RenovoRx

RenovoRx RenovoRx (Nasdaq: RNXT) is developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device.

02/24/2026

In a Medsider interview, RenovoRx CEO, Shaun Bagai, discusses the foundation of the Company’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform and shares how early lessons from his career have helped shape the Company’s commercialization strategy into a well-defined market. For more: https://bit.ly/4arHefp

The newly formed RenovoCath Medical Advisory Board’s collective expertise will help guide real-world evidence generation...
02/11/2026

The newly formed RenovoCath Medical Advisory Board’s collective expertise will help guide real-world evidence generation as we advance our novel approach to localized, targeted drug delivery, aiming to improve outcomes for patients diagnosed with difficult-to-treat cancers. For more: https://bit.ly/4at7817

We are pleased to announce the formation of a dedicated RenovoCath Medical Advisory Board, bringing together leading US ...
02/10/2026

We are pleased to announce the formation of a dedicated RenovoCath Medical Advisory Board, bringing together leading US interventional radiology experts to provide strategic clinical insights that further advance the TAMP™ therapy platform in clinical indications of high unmet medical need. For details: https://bit.ly/4at7817

Join us on Saturday, February 7th, 1:45–2:00 PM ET, at SIO 2026 for an engaging presentation by expert interventional on...
02/06/2026

Join us on Saturday, February 7th, 1:45–2:00 PM ET, at SIO 2026 for an engaging presentation by expert interventional oncologists, Dr. Paula Novelli, UPMC, and Dr. Khashayar Farsad, OHSU. They will share their real-world insights and potential benefits on the use of the TAMP™ therapy platform for oncology management. https://bit.ly/46l7RB2

Christopher Laing, MD of Sutter Health comments on the clinical data supporting the TAMP™ therapy platform which will be...
02/05/2026

Christopher Laing, MD of Sutter Health comments on the clinical data supporting the TAMP™ therapy platform which will be presented at the SIO 2026 tomorrow, February 6th. For more info, visit: https://bit.ly/3ZcZYJj

We’re pleased to welcome Mark Voll as RenovoRx’s Chief Financial Officer, effective February 1, 2026. He joins our leade...
02/05/2026

We’re pleased to welcome Mark Voll as RenovoRx’s Chief Financial Officer, effective February 1, 2026. He joins our leadership team during an important chapter of RenovoRx’s commercial growth. Learn more: https://bit.ly/49YDeCX

On , RenovoRx joins the global community in raising awareness about the urgent need for innovative treatment options fo...
02/05/2026

On , RenovoRx joins the global community in raising awareness about the urgent need for innovative treatment options for patients diagnosed with difficult-to-treat cancers.

At RenovoRx, we are committed to transforming the lives of patients with cancer through targeted chemotherapeutic delivery via the TAMP™ therapy platform.

Together, we continue the fight against cancer. www.worldcancerday.org

We are excited that clinical data supporting TAMP’s novel approach to targeted, pressure-mediated chemotherapeutic deliv...
02/04/2026

We are excited that clinical data supporting TAMP’s novel approach to targeted, pressure-mediated chemotherapeutic delivery and reinforcing its potential to provide individualized, optimized drug-delivery, will be presented at the SIO 2026 this Friday, February 6th at 5:45-6:00 PM ET. For details: https://bit.ly/3ZcZYJj

Attending 2026 SIO Annual Scientific Meeting this week? A clinical data abstract will be presented providing supportive ...
02/03/2026

Attending 2026 SIO Annual Scientific Meeting this week? A clinical data abstract will be presented providing supportive evidence for RenovoRx’s TAMP™ therapy platform’s novel approach to targeted, pressure-mediated drug-delivery. Visit us at Booth #419 to learn more. https://bit.ly/3Z4Ois0

Listen to The Leading Difference podcast to hear our CEO, Shaun Bagai, discuss his definition of effective leadership, e...
02/03/2026

Listen to The Leading Difference podcast to hear our CEO, Shaun Bagai, discuss his definition of effective leadership, emphasizing continuous learning, growth, and purpose-driven decision-making. For more: https://bit.ly/3ZzZ0GZ

Our CEO, Shaun Bagai, spoke with Genetic Engineering & Biotechnology News about RenovoRx's novel drug delivery Trans-Art...
01/29/2026

Our CEO, Shaun Bagai, spoke with Genetic Engineering & Biotechnology News about RenovoRx's novel drug delivery Trans-Arterial Micro-Perfusion (TAMP™) therapy platform and the ongoing Phase III TIGeR‑PaC clinical trial in . Read the article here: https://bit.ly/49Oadsp

The RenovoRx team is excited that a clinical data abstract supporting the TAMP™ therapy platform has been accepted at th...
01/28/2026

The RenovoRx team is excited that a clinical data abstract supporting the TAMP™ therapy platform has been accepted at the upcoming 2026 SIO Annual Scientific Meeting. The abstract provides supportive evidence for TAMP’s novel approach to targeted, pressure-mediated drug-delivery. The meeting will be held February 4–8, 2026 in Savannah, Georgia. For details: https://bit.ly/3Z4Ois0

Address

Mountain View, CA

Website

Alerts

Be the first to know and let us send you an email when RenovoRx posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to RenovoRx:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram